Affluent Medical SAS Asset Resilience Ratio

Latest as of June 2025: 0.03%

Affluent Medical SAS asset resilience ratio. Affluent Medical SAS (AFME) has an Asset Resilience Ratio of 0.03% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Affluent Medical SAS to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€15.00K
≈ $17.54K USD Cash + Short-term Investments

Total Assets

€59.84 Million
≈ $69.96 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Affluent Medical SAS (2016–2024)

Asset resilience ratio of Affluent Medical SAS from 2016 to 2024. This chart shows how Affluent Medical SAS's Asset Resilience Ratio has changed over time. Read AFME total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Affluent Medical SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Affluent Medical SAS balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €15.00K 0.03%
Total Liquid Assets €15.00K 0.03%

Asset Resilience Insights

  • Limited Liquidity: Affluent Medical SAS maintains only 0.03% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Affluent Medical SAS Industry Peers by Asset Resilience Ratio

Compare Affluent Medical SAS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
T&L Co. Ltd
KQ:340570
Medical Devices 26.03%
Paxman AB
ST:PAX
Medical Devices -3.83%
VIROMED MEDICAL NA O.N.
XETRA:VME
Medical Devices 0.03%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.48%
Pulsenmore Ltd
TA:PULS
Medical Devices 51.61%
Geratherm Medical AG
XETRA:GME
Medical Devices 34.89%

Affluent Medical SAS Asset Resilience Ratio by Year (2016–2024)

Affluent Medical SAS asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Affluent Medical SAS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 10.88% €6.62 Million
≈ $7.74 Million
€60.86 Million
≈ $71.15 Million
+7.95pp
2023-12-31 2.93% €1.66 Million
≈ $1.94 Million
€56.62 Million
≈ $66.20 Million
-1.31pp
2022-12-31 4.24% €2.54 Million
≈ $2.98 Million
€60.02 Million
≈ $70.17 Million
-11.88pp
2021-12-31 16.12% €11.29 Million
≈ $13.20 Million
€70.03 Million
≈ $81.88 Million
+7.53pp
2020-12-31 8.60% €5.57 Million
≈ $6.51 Million
€64.83 Million
≈ $75.79 Million
+5.34pp
2019-12-31 3.26% €2.13 Million
≈ $2.49 Million
€65.25 Million
≈ $76.29 Million
-4.14pp
2017-12-31 7.40% €4.99 Million
≈ $5.83 Million
€67.39 Million
≈ $78.79 Million
+4.51pp
2016-12-31 2.90% €1.79 Million
≈ $2.09 Million
€61.72 Million
≈ $72.16 Million
--
pp = percentage points

About Affluent Medical SAS

PA:AFME France Medical Devices
Market Cap
$129.10 Million
€110.43 Million EUR
Market Cap Rank
#18636 Global
#271 in France
Share Price
€2.81
Change (1 day)
+0.36%
52-Week Range
€1.33 - €2.81
All Time High
€8.30
About

Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more